Send to printer »

GEN News Highlights : Feb 6, 2009

Health Discovery Enters Deals with Abbott and Quest Diagnostics for Prostate Cancer Tests

Abbott will commercialize HDC’s diagnostics, and Quest Diagnostics will leverage the firm’s biomarkers for a new test.

Health Discovery (HDC) inked two separate agreements related to its prostate cancer diagnostic program. It has given Abbott the right to commercialize its gene-based tests for clinically significant prostate cancer.

Abbott acquired coexclusive clinical laboratory rights and exclusive in vitro diagnostic rights for HDC’s tissue-based and urine-based prostate cancer test.

Additionally, HDC licensed rights to Quest Diagnostics for the development of a urine-based test for clinically significant prostate cancer. Under the terms of this agreement, HDC will receive payments, royalties, and additional undisclosed financial considerations.

---

To comment on this story, go to BLOGbiotech.